Angina Clinical Trial - Impact of Coronary Anatomy on Angina Relief in

Status Completed

Clinical Trial Summary

We hypothesize that Coronary Artery Disease (CAD) severity assessed by SYNTAX score is an independent predictor of recurrent or persistent angina following coronary revascularization. The SYNTAX score is a score that suggests the severity of coronary artery disease detected by coronary angiography. Coronary revascularization is a procedure that occurs in two ways, a percutaneous coronary intervention (PCI) and a coronary artery bypass graft (CABG) and is done when there is narrowing and blockage or hardening of the arteries (atherosclerosis) surrounding the heart. Narrowing and blockages reduce blood flow to parts of the heart causing chest pain (known as angina) and sometimes myocardial infarction.

Clinical Trial Description

PCI and CABG are two well-established revascularization approaches to treatment of chronic angina caused by coronary atherosclerosis. Nevertheless, 35-42% of patients report recurring or persisting anginal symptoms after coronary revascularization. This can be attributed to many structural and functional causes, prominent amongst which is pre-revascularization angina severity, unrevascularized coronary territory, progression of native or bypass graft atherosclerosis, restenosis (re-narrowing of the vessels) and accompanying adjunctive pharmacotherapy.

The SYNTAX score is an angiographic tool for grading the complexity of coronary disease. It is the sum of points assigned to coronary lesions within one of the 16 segments of the coronary tree. The segments are given a 1,2, or 5 based on the disease presence as defined by the American Heart Association classification. The SYNTAX score has been used to help predict the outcomes of patients undergoing PCI with 3-vessel involvement (e.g. a triple bypass or 3-stent placement PCI). Those patients with the highest scores had the highest risk of a poor outcome with PCI revascularization compared to CABG. Despite these observations, the impact of CAD severity on post-revascularization angina, using the SYNTAX has never been systematically addressed in the current era. ;

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01665833
Study type	Observational
Source	North Texas Veterans Healthcare System
Contact
Status	Completed
Phase	N/A
Start date	January 2003
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04097912` - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Withdrawn	`NCT03134105` - A Wearable EducAtional Intervention to REduce Angina	N/A
Completed	`NCT02832115` - Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention	Phase 4
Completed	`NCT02265796` - Ranolazine Among Unrevascularized Chronic Stable Angina Patients	Phase 2
Terminated	`NCT00221182` - Stem Cell Study for Patients With Heart Disease	Phase 1/Phase 2
Completed	`NCT01721096` - XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Recruiting	`NCT01214499` - Prospective, Controlled and Randomized Clinical Trial on Cardiac Cell Regeneration With Laser and Autologous Bone Marrow Stem Cells, in Patients With Coronary Disease and Refractory Angina	Phase 2
Terminated	`NCT01285297` - Safety Study of Transmyocardial Revascularization (TMR) With Bone Marrow Aspirate (BMAC) for Angina Reduction	N/A
Withdrawn	`NCT00774891` - Comparison Of Left Ventricular Volume And Wall Stress With Dobutamine And Exercise Echocardiography	N/A
Completed	`NCT02707783` - Feasibility and Outcomes of Complete Coronary Revascularization Using BVS in All-comer Patients With Angina
Completed	`NCT02065102` - Optical Coherence Tomography to Improve Clinical Outcomes During Coronary Angioplasty	N/A
Completed	`NCT00946725` - To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg	Phase 1
Recruiting	`NCT02439541` - Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy	Phase 1/Phase 2
Completed	`NCT02341664` - Patient and Provider Assessment of Lipid Management Registry
Withdrawn	`NCT00657514` - Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease	Phase 4
Recruiting	`NCT01361659` - Shockwave Treatment for Advanced Angina in Maastricht	N/A
Recruiting	`NCT05786417` - LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions	Phase 4
Withdrawn	`NCT02507050` - Ivabradine and Post-revascularisation Microcirculatory Dysfunction	Phase 4
Active, not recruiting	`NCT02468960` - Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds (OPreNBiS)	N/A
Completed	`NCT01086228` - XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of Coronary Anatomy on Angina Relief in Patients Undergoing Coronary Revascularization

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms